Table of Content


Introduction
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Antisense Therapeutics Ltd, 2021
Pipeline by Aviara Pharmaceuticals Inc, 2021
Pipeline by AxeroVision Inc, 2021
Pipeline by Biogen Inc, 2021
Pipeline by C4X Discovery Holdings Plc, 2021
Pipeline by DiCE Molecules SV Inc, 2021
Pipeline by EA Pharma Co Ltd, 2021
Pipeline by Feramda Ltd, 2021
Pipeline by Genentech USA Inc, 2021
Pipeline by Gilead Sciences Inc, 2021
Pipeline by Immunwork Inc, 2021
Pipeline by Morphic Therapeutic Inc, 2021
Pipeline by Polpharma Biologics SA, 2021
Pipeline by Progenity Inc, 2021
Pipeline by Protagonist Therapeutics Inc, 2021
Pipeline by Regenerative Arthritis & Bone Medicine Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Tolerion Inc, 2021
Pipeline by Zealand Pharma AS, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021